Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks

J. Andrew Grant, Martha V. White, H. Henry Li, David Fitts, Ira N. Kalfus, Marc E. Uknis, William R. Lumry

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Patients with hereditary angioedema (HAE) may have attacks triggered by dental, medical, or surgical procedures. This analysis evaluated the efficacy and safety of preprocedural administration of nanofiltered C1 esterase inhibitor (C1 INH-nf; human) for the prevention of HAE attacks during and after dental, medical, or surgical procedures. Data were reviewed retrospectively from two acute treatment trials in which at least 1000 U of C1 INH-nf was administered i.v. within 24 hours before an emergency or noncosmetic medical, surgical, or dental procedure. Dosing data, HAE attacks reported within 72 hours, and adverse events (AEs) reported within 7 days after a preprocedural dose of C1 INH-nf were analyzed to assess efficacy and safety. Forty-one unique subjects (8 children and 33 adults) received C1 INH-nf for 91 procedures (40 in children and 51 in adults). The majority of procedures (56%) involved dental work and 44% involved a variety of surgical or medical procedures. A single 1000-U dose of C1 INH-nf was administered for 96% of procedures. An HAE attack did not occur within 72 hours after C1 INH-nf dosing for 98% (89/91) of procedures. Two HAE attacks were reported after the procedure, and both were treated with C1 INH-nf and achieved relief. None of the reported AEs were judged to be related to C1 INH-nf or were associated with an HAE attack. This analysis supports the efficacy and safety of preprocedural administration of C1 INH-nf for the prevention of HAE attacks.

Original languageEnglish (US)
Pages (from-to)348-353
Number of pages6
JournalAllergy and Asthma Proceedings
Volume33
Issue number4
DOIs
StatePublished - Jul 2012

Fingerprint

Complement C1 Inhibitor Protein
Hereditary Angioedemas
Tooth
Safety
Emergencies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Grant, J. A., White, M. V., Li, H. H., Fitts, D., Kalfus, I. N., Uknis, M. E., & Lumry, W. R. (2012). Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. Allergy and Asthma Proceedings, 33(4), 348-353. https://doi.org/10.2500/aap.2012.33.3585

Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. / Grant, J. Andrew; White, Martha V.; Li, H. Henry; Fitts, David; Kalfus, Ira N.; Uknis, Marc E.; Lumry, William R.

In: Allergy and Asthma Proceedings, Vol. 33, No. 4, 07.2012, p. 348-353.

Research output: Contribution to journalArticle

Grant, J. Andrew ; White, Martha V. ; Li, H. Henry ; Fitts, David ; Kalfus, Ira N. ; Uknis, Marc E. ; Lumry, William R. / Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. In: Allergy and Asthma Proceedings. 2012 ; Vol. 33, No. 4. pp. 348-353.
@article{025144f437014e8a8ac8f349913ba892,
title = "Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks",
abstract = "Patients with hereditary angioedema (HAE) may have attacks triggered by dental, medical, or surgical procedures. This analysis evaluated the efficacy and safety of preprocedural administration of nanofiltered C1 esterase inhibitor (C1 INH-nf; human) for the prevention of HAE attacks during and after dental, medical, or surgical procedures. Data were reviewed retrospectively from two acute treatment trials in which at least 1000 U of C1 INH-nf was administered i.v. within 24 hours before an emergency or noncosmetic medical, surgical, or dental procedure. Dosing data, HAE attacks reported within 72 hours, and adverse events (AEs) reported within 7 days after a preprocedural dose of C1 INH-nf were analyzed to assess efficacy and safety. Forty-one unique subjects (8 children and 33 adults) received C1 INH-nf for 91 procedures (40 in children and 51 in adults). The majority of procedures (56{\%}) involved dental work and 44{\%} involved a variety of surgical or medical procedures. A single 1000-U dose of C1 INH-nf was administered for 96{\%} of procedures. An HAE attack did not occur within 72 hours after C1 INH-nf dosing for 98{\%} (89/91) of procedures. Two HAE attacks were reported after the procedure, and both were treated with C1 INH-nf and achieved relief. None of the reported AEs were judged to be related to C1 INH-nf or were associated with an HAE attack. This analysis supports the efficacy and safety of preprocedural administration of C1 INH-nf for the prevention of HAE attacks.",
author = "Grant, {J. Andrew} and White, {Martha V.} and Li, {H. Henry} and David Fitts and Kalfus, {Ira N.} and Uknis, {Marc E.} and Lumry, {William R.}",
year = "2012",
month = "7",
doi = "10.2500/aap.2012.33.3585",
language = "English (US)",
volume = "33",
pages = "348--353",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks

AU - Grant, J. Andrew

AU - White, Martha V.

AU - Li, H. Henry

AU - Fitts, David

AU - Kalfus, Ira N.

AU - Uknis, Marc E.

AU - Lumry, William R.

PY - 2012/7

Y1 - 2012/7

N2 - Patients with hereditary angioedema (HAE) may have attacks triggered by dental, medical, or surgical procedures. This analysis evaluated the efficacy and safety of preprocedural administration of nanofiltered C1 esterase inhibitor (C1 INH-nf; human) for the prevention of HAE attacks during and after dental, medical, or surgical procedures. Data were reviewed retrospectively from two acute treatment trials in which at least 1000 U of C1 INH-nf was administered i.v. within 24 hours before an emergency or noncosmetic medical, surgical, or dental procedure. Dosing data, HAE attacks reported within 72 hours, and adverse events (AEs) reported within 7 days after a preprocedural dose of C1 INH-nf were analyzed to assess efficacy and safety. Forty-one unique subjects (8 children and 33 adults) received C1 INH-nf for 91 procedures (40 in children and 51 in adults). The majority of procedures (56%) involved dental work and 44% involved a variety of surgical or medical procedures. A single 1000-U dose of C1 INH-nf was administered for 96% of procedures. An HAE attack did not occur within 72 hours after C1 INH-nf dosing for 98% (89/91) of procedures. Two HAE attacks were reported after the procedure, and both were treated with C1 INH-nf and achieved relief. None of the reported AEs were judged to be related to C1 INH-nf or were associated with an HAE attack. This analysis supports the efficacy and safety of preprocedural administration of C1 INH-nf for the prevention of HAE attacks.

AB - Patients with hereditary angioedema (HAE) may have attacks triggered by dental, medical, or surgical procedures. This analysis evaluated the efficacy and safety of preprocedural administration of nanofiltered C1 esterase inhibitor (C1 INH-nf; human) for the prevention of HAE attacks during and after dental, medical, or surgical procedures. Data were reviewed retrospectively from two acute treatment trials in which at least 1000 U of C1 INH-nf was administered i.v. within 24 hours before an emergency or noncosmetic medical, surgical, or dental procedure. Dosing data, HAE attacks reported within 72 hours, and adverse events (AEs) reported within 7 days after a preprocedural dose of C1 INH-nf were analyzed to assess efficacy and safety. Forty-one unique subjects (8 children and 33 adults) received C1 INH-nf for 91 procedures (40 in children and 51 in adults). The majority of procedures (56%) involved dental work and 44% involved a variety of surgical or medical procedures. A single 1000-U dose of C1 INH-nf was administered for 96% of procedures. An HAE attack did not occur within 72 hours after C1 INH-nf dosing for 98% (89/91) of procedures. Two HAE attacks were reported after the procedure, and both were treated with C1 INH-nf and achieved relief. None of the reported AEs were judged to be related to C1 INH-nf or were associated with an HAE attack. This analysis supports the efficacy and safety of preprocedural administration of C1 INH-nf for the prevention of HAE attacks.

UR - http://www.scopus.com/inward/record.url?scp=84864767139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864767139&partnerID=8YFLogxK

U2 - 10.2500/aap.2012.33.3585

DO - 10.2500/aap.2012.33.3585

M3 - Article

VL - 33

SP - 348

EP - 353

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 4

ER -